Bal Pharma Limited (BALPHARMA.NS)
INR 120.5
(-0.08%)
INR 120.5
(-0.08%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 3.2 Billion INR | 2.3% |
| 2022 | 3.13 Billion INR | 20.2% |
| 2021 | 2.6 Billion INR | 8.52% |
| 2020 | 2.4 Billion INR | 0.71% |
| 2019 | 2.38 Billion INR | -8.77% |
| 2018 | 2.61 Billion INR | 3.77% |
| 2017 | 2.51 Billion INR | 9.38% |
| 2016 | 2.3 Billion INR | 9.09% |
| 2015 | 2.11 Billion INR | 28.78% |
| 2014 | 1.63 Billion INR | 5.89% |
| 2013 | 1.54 Billion INR | 3.27% |
| 2012 | 1.49 Billion INR | 6.14% |
| 2011 | 1.41 Billion INR | 4.33% |
| 2010 | 1.35 Billion INR | 8.94% |
| 2009 | 1.24 Billion INR | 2.19% |
| 2008 | 1.21 Billion INR | 11.66% |
| 2007 | 1.08 Billion INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 3.2 Billion INR | 0.0% |
| 2023 Q2 | 3.29 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 3.2 Billion INR | 2.3% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 2.91 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 3.13 Billion INR | 20.2% |
| 2022 Q4 | 3.13 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 2.59 Billion INR | 0.0% |
| 2021 FY | 2.6 Billion INR | 8.52% |
| 2021 Q4 | 2.6 Billion INR | 0.0% |
| 2020 Q4 | 2.4 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 2.53 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 2.4 Billion INR | 0.71% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 2.38 Billion INR | -8.77% |
| 2019 Q2 | 2.44 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q4 | 2.38 Billion INR | 0.0% |
| 2018 Q4 | 2.61 Billion INR | 0.0% |
| 2018 FY | 2.61 Billion INR | 3.77% |
| 2017 FY | 2.51 Billion INR | 9.38% |
| 2017 Q4 | 2.51 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 FY | 2.3 Billion INR | 9.09% |
| 2016 Q4 | 2.3 Billion INR | 0.0% |
| 2016 Q2 | 2.16 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 FY | 2.11 Billion INR | 28.78% |
| 2015 Q4 | 2.11 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q2 | 1.94 Billion INR | 0.0% |
| 2014 Q2 | 1.6 Billion INR | 0.0% |
| 2014 FY | 1.63 Billion INR | 5.89% |
| 2014 Q4 | 1.63 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q1 | - INR | -100.0% |
| 2013 Q2 | 1.62 Billion INR | 0.0% |
| 2013 Q4 | 1.54 Billion INR | 0.0% |
| 2013 FY | 1.54 Billion INR | 3.27% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q3 | - INR | -100.0% |
| 2012 Q2 | 1.42 Billion INR | 0.0% |
| 2012 FY | 1.49 Billion INR | 6.14% |
| 2012 Q4 | 1.49 Billion INR | 0.0% |
| 2011 Q4 | 1.41 Billion INR | 0.0% |
| 2011 FY | 1.41 Billion INR | 4.33% |
| 2010 FY | 1.35 Billion INR | 8.94% |
| 2009 FY | 1.24 Billion INR | 2.19% |
| 2008 FY | 1.21 Billion INR | 11.66% |
| 2007 FY | 1.08 Billion INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Sigachi Industries Limited | 6.94 Billion INR | 53.845% |
| Ind-Swift Limited | 6.54 Billion INR | 51.046% |
| Bajaj HealthCare Limited | 7.65 Billion INR | 58.126% |
| Sakar Healthcare Limited | 3.88 Billion INR | 17.566% |
| Aurobindo Pharma Limited | 450.71 Billion INR | 99.289% |
| Innova Captab Limited | 13.2 Billion INR | 75.744% |
| Divi's Laboratories Limited | 154.7 Billion INR | 97.929% |
| AstraZeneca Pharma India Limited | 10.78 Billion INR | 70.28% |
| Morepen Laboratories Limited | 12.93 Billion INR | 75.225% |
| Mankind Pharma Limited | 119.63 Billion INR | 97.322% |
| Sequent Scientific Limited | 15.4 Billion INR | 79.201% |
| Wanbury Limited | 3.43 Billion INR | 6.726% |
| Laurus Labs Limited | 83.87 Billion INR | 96.18% |
| Nectar Lifesciences Limited | 21.91 Billion INR | 85.377% |
| Glenmark Life Sciences Limited | 28.5 Billion INR | 88.76% |
| Alembic Limited | 23.28 Billion INR | 86.242% |
| Hikal Limited | 24.87 Billion INR | 87.118% |
| Alembic Pharmaceuticals Limited | 64.45 Billion INR | 95.029% |
| Neuland Laboratories Limited | 18.32 Billion INR | 82.517% |
| J. B. Chemicals & Pharmaceuticals Limited | 39.94 Billion INR | 91.979% |
| Glenmark Pharmaceuticals Limited | 143.58 Billion INR | 97.769% |
| IOL Chemicals and Pharmaceuticals Limited | 22.44 Billion INR | 85.725% |
| Themis Medicare Limited | 5.66 Billion INR | 43.436% |
| RPG Life Sciences Limited | 5.12 Billion INR | 37.53% |
| Zydus Lifesciences Limited | 292.8 Billion INR | 98.906% |
| Lupin Limited | 239.97 Billion INR | 98.665% |
| Amrutanjan Health Care Limited | 3.66 Billion INR | 12.67% |
| Wockhardt Limited | 76.49 Billion INR | 95.811% |
| Vaishali Pharma Limited | 799.55 Million INR | -300.708% |
| Aarti Pharmalabs Limited | 25.82 Billion INR | 87.592% |
| Jagsonpal Pharmaceuticals Limited | 2.17 Billion INR | -47.592% |
| Jubilant Pharmova Limited | 115.48 Billion INR | 97.226% |
| FDC Limited | 24.68 Billion INR | 87.019% |
| Dr. Reddy's Laboratories Limited | 387.51 Billion INR | 99.173% |
| Kilitch Drugs (India) Limited | 2.4 Billion INR | -33.461% |
| Eris Lifesciences Limited | 70.48 Billion INR | 95.455% |
| Venus Remedies Limited | 6.26 Billion INR | 48.887% |
| ZIM Laboratories Limited | 4.46 Billion INR | 28.296% |
| Bliss GVS Pharma Limited | 12.13 Billion INR | 73.606% |
| Par Drugs and Chemicals Limited | 1.01 Billion INR | -215.309% |
| Caplin Point Laboratories Limited | 26.97 Billion INR | 88.122% |
| Shilpa Medicare Limited | 30.93 Billion INR | 89.642% |
| Albert David Limited | 4.97 Billion INR | 35.664% |
| Ajanta Pharma Limited | 46.38 Billion INR | 93.093% |
| Hester Biosciences Limited | 6.62 Billion INR | 51.628% |
| Suven Pharmaceuticals Limited | 22.54 Billion INR | 85.786% |
| Solara Active Pharma Sciences Limited | 23.46 Billion INR | 86.347% |
| Gufic Biosciences Limited | 10.92 Billion INR | 70.675% |
| Windlas Biotech Limited | 6.26 Billion INR | 48.836% |
| Procter & Gamble Health Limited | 7.94 Billion INR | 59.667% |
| Aarey Drugs & Pharmaceuticals Limited | 3.04 Billion INR | -5.048% |
| Mangalam Drugs & Organics Limited | 3.33 Billion INR | 3.909% |
| Granules India Limited | 55.2 Billion INR | 94.197% |
| Aarti Drugs Limited | 24.32 Billion INR | 86.828% |
| Alkem Laboratories Limited | 155.74 Billion INR | 97.943% |
| Sun Pharmaceutical Industries Limited | 854.62 Billion INR | 99.625% |
| Lincoln Pharmaceuticals Limited | 7 Billion INR | 54.249% |
| Medicamen Biotech Limited | 2.94 Billion INR | -8.783% |
| Unichem Laboratories Limited | 31.69 Billion INR | 89.891% |
| Bafna Pharmaceuticals Limited | 1.47 Billion INR | -116.946% |
| Biofil Chemicals and Pharmaceuticals Limited | 470.82 Million INR | -580.481% |
| Valiant Laboratories Limited | 3.42 Billion INR | 6.507% |
| Orchid Pharma Limited | 15.53 Billion INR | 79.381% |
| Medico Remedies Limited | 961.95 Million INR | -233.061% |
| Ind-Swift Laboratories Limited | 11.65 Billion INR | 72.501% |
| Ipca Laboratories Limited | 111.01 Billion INR | 97.114% |
| Brooks Laboratories Limited | 904.45 Million INR | -254.235% |
| Syncom Formulations (India) Limited | 4.04 Billion INR | 20.826% |
| Piramal Enterprises Limited | 826.05 Billion INR | 99.612% |
| Torrent Pharmaceuticals Limited | 150.61 Billion INR | 97.873% |
| NATCO Pharma Limited | 69.06 Billion INR | 95.361% |
| Suven Life Sciences Limited | 2.84 Billion INR | -12.456% |
| Krebs Biochemicals & Industries Limited | 1.78 Billion INR | -79.817% |
| Strides Pharma Science Limited | 58.39 Billion INR | 94.514% |
| Indoco Remedies Limited | 21.44 Billion INR | 85.062% |
| Alpa Laboratories Limited | 1.82 Billion INR | -75.439% |
| Lasa Supergenerics Limited | 1.5 Billion INR | -112.363% |
| Sun Pharma Advanced Research Company Limited | 5.15 Billion INR | 37.793% |